The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Negasheva E.S.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Frigo N.V.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia;
State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia

Popova E.A.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Vasil’tsova M.Yu.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Gushchin A.E.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Kitaeva N.V.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Modern approaches to the treatment of NCMT sexually transmitted infections (N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis). Part I. N. gonorrhoeae, C. trachomatis

Authors:

Negasheva E.S., Frigo N.V., Popova E.A., Vasil’tsova M.Yu., Gushchin A.E., Kitaeva N.V., Potekaev N.N.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2026;25(2): 243‑253

DOI: 10.17116/klinderma202625021243

Read: 327 times

Contact the author
Table of contents

MODERN APPROACHES TO THE TREATMENT OF NCMT SEXUALLY TRANSMITTED INFECTIONS (N. GONORRHOEAE, C. TRACHOMATIS, M. GENITALIUM, T. VAGINALIS). PART I. N. GONORRHOEAE, C. TRACHOMATIS
MODERN APPROACHES TO THE TREATMENT OF NCMT SEXUALLY TRANSMITTED INFECTIONS (N. GONORRHOEAE, C. TRACHOMATIS, M. GENITALIUM, T. VAGINALIS). PART I. N. GONORRHOEAE, C. TRACHOMATIS

To cite this article:

Negasheva ES, Frigo NV, Popova EA, Vasil’tsova MYu, Gushchin AE, Kitaeva NV, Potekaev NN. Modern approaches to the treatment of NCMT sexually transmitted infections (N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis). Part I. N. gonorrhoeae, C. trachomatis. Russian Journal of Clinical Dermatology and Venereology. 2026;25(2):243‑253. (In Russ.)
https://doi.org/10.17116/klinderma202625021243

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Vaccination against pneumococcal infe­ction as a mean of redu­cing morbidity and mortality of the adult popu­lation from risk groups in the Russian Fede­ration. (Resolution of the Council of Expe­rts). Russian Journal of Preventive Medi­cine. 2025;(7):7-14
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Main trends in the epidemiology of mali­gnant neoplasms in the Sibe­rian Fede­ral district. P.A. Herzen Journal of Onco­logy. 2025;(4):61-68
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Atte­ndance of dental surgeons for diseases in the Russian Fede­ration in 2017—2023. Stomatology. 2025;(4):62-65
Analysis of morbidity in the Gomel region of Repu­blic Bela­rus. Russian Journal of Preventive Medi­cine. 2025;(9):23-28
Biological and geno­mic characterisation of phage Ec2-7 with anti­microbial acti­vity against STEC strains Escherichia coli. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(3):31-35
Dyna­mics of microbial colo­nization in various biotopes of preterm neonates with extremely low and very low birth weight: a pilot study. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):35-43
Current global trends in the epidemiology of inflammatory bowel diseases. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):104-117
Community-acquired pneumonia in adults. Clinical guidelines 2024 (short version). Journal of Respiratory Medi­cine. 2025;(3):6-18
Abstract:

An analysis of the literature on modern approaches to the treatment of two sexually transmitted infections reported in various countries, namely gonococcal and chlamydial, is presented. Retrospective information on the incidence of these infections in the countries of Europe, Russia and the USA in recent years and current recommendations for the treatment of uncomplicated forms of gonococcal and urogenital chlamydial infections from the IUSTI (International Union against Sexually Transmitted Infections), CDC (Centers for Disease Control and Prevention) guidelines, Russian clinical guidelines dated 2024 and the WHO data are provided. The data of modern studies on resistance of N. gonorrhoeae to antimicrobial drugs in countries of the world and in the Russian Federation are presented. The main causes of treatment failures were analyzed. Among them, according to researchers in various countries, it is antibiotic resistance of N. gonorrhoeae for gonococcal infection, and for chlamydial — a set of causes, including non-compliance with therapy regimes, false positive diagnosis of urogenital chlamydial infection after completion of therapy, human genital microbiome status, persistence and high bacterial load of C. trachomatis.

Keywords:

sexually transmitted infections
gonococcal infection
chlamydial infection
N.gonorrhoeae
C.trachomatis
incidence
antibiotic resistance
therapy

Authors:

Negasheva E.S.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Frigo N.V.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia;
State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia

Popova E.A.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Vasil’tsova M.Yu.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Gushchin A.E.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Kitaeva N.V.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Received:

24.03.2025

Accepted:

09.01.2026

Close metadata

References:

  1. Gushchin AE, Ryzhih PG, Savochkina YuA, Shipulina OYu, Shipu-lin GA. Study of the prevalence of STI pathogens (C. trachomatis, N. gonorrhoeae, M. genitalium, T. vaginalis) using real-time PCR in the «MULTIPRIME» format. Russian Journal of Clinical Dermatology and Venereology. 2011;4:90-93. (In Russ.).
  2. Aguilera-Franco M, Tarriño-León M, Olivares-Durán MJ, Espadafor B, Rodríguez-Granger J, Reguera JA, Cobo F, Sampedro A, Navarro JM. Evaluation of a new CT/NG/TV/MG Real-Time PCR Kit (Vircell) versus the Allplex STI Essential Assay (Seegene) for the diagnosis of sexually transmitted infections. J Med Microbiol. 2024 Apr;73(4):without pages. https://doi.org/10.1099/jmm.0.001797
  3. Reda S, Gonçalves FA, Mazepa MM, De Carvalho NS. Women infected with HIV and the impact of associated sexually transmitted infections. Int J Gynaecol Obstet. 2018;142(2):143-147.  https://doi.org/10.1002/ijgo.12507
  4. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N, Taylor MM. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97:548P-562P. https://doi.org/10.2471/BLT.18.228486
  5. European Centre for Disease Prevention and Control (ECDC). Facts about gonorrhoea. Accessed Mar 19, 2025; European Centre for Disease Prevention and Control (ECDC). https://www.ecdc.europa.eu/en/gonorrhoea/facts2
  6. CDC. STI Statistics. Sexually Transmitted Infections Surveillance, 2023. https://www.cdc.gov/std/treatment-guidelines/toc.htm
  7. Resursy i deyatel’nost’ medicinskih organizacij dermatovenerolo-gicheskogo profilya. Zabolevaemost’ infekciyami, peredavaemymi polovym putem, zaraznymi kozhnymi boleznyami i boleznyami kozhi v 2023 godu: stati-sticheskie materialy. IA Deev, OS Kobyakova, AA Kubanov, VI Starodubov, GA Aleksandrova, EV Bogdanova, NA Golubev, DA Kucheryavaya, LE Melekhina, EV Ogryzko, AV Polikarpov, EA Shelepova, et al. M.: CNIIOIZ Minzdrava Rossii; 2024. (In Russ.).
  8. Unemo M, Ross JDC, Serwin AB, Gomberg M, Cusini M, Jensen JS. European guideline for the diagnosis and treatment of gonorrhoea in adults. International Journal of STD & AIDS. 2020;0(0):1-17. 
  9. Sexually Transmitted Infections Treatment Guidelines, 2021, Accessed Mar 19, 2025. https://www.cdc.gov/std/treatment-guidelines/toc.htm
  10. Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new recommendations on syphilis testing and partner services; Geneva: World Health Organization; 2024. [Internet]. Accessed Mar 19, 2025. https://www.ncbi.nlm.nih.gov/books/NBK605892/
  11. Klinicheskie rekomendacii Gonokokkovaya infekciya. God utverzhdeniya: 2024. Accessed Mar 19, 2025. (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/218_2
  12. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis. 2013;56:1539-1545.
  13. Harris SR, Cole MJ, Spiteri G, et al. Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infect Dis. 2018;18:758-768. 
  14. European Centre for Disease Prevention and Control (ECDC). European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP). Accessed Fev 17, 2025. https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/euro-gasp10
  15. Kubanov AA, Rahmatulina MR, Solomka VS, Plahova KI, Chestkov AV, Petrova NP, Deryabin DG. Neisseria gonorrhoeae antibiotic resistance in the Russian Federation: current trends. Klin mikrobiol antimikrob himioter. 2016;18(4):282-290. (In Russ.).
  16. European Medicines Agency. Review of quinolone- and fluoroquinolone-containing medicinal products, Accessed Mar 19, 2025. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products
  17. Awoke Derbie, Daniel Mekonnen, Yimtubezinash Woldeamanuel, Tamrat Abebe. Azithromycin resistant gonococci: a literature review. Antimicrob Resist Infect Control. 2020 Aug 18;9(1):138.  https://doi.org/10.1186/s13756-020-00805-7
  18. Solomka VS, Kubanov AA, Plahova KI, Chestkov AV, Petrova NP, Deryabin DG. Neisseria gonorrhoeae antibiotic resistance in the Russian Federation: regional features. Klinicheskaya mikrobiologiya i antimikrobnaya terapiya. 2017;19(2):153-159. (In Russ.).
  19. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65:2141-2148. https://doi.org/10.1093/jac/dkq289
  20. Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE. Pharmacokinetic data are predictive of in vivo efficacy for cefixime and ceftriaxone against susceptible and resistant Neisseria gonorrhoeae strains in the gonorrhea mouse model. Antimicrob Agents Chemother. 2019;63:e01644-18.  https://doi.org/10.1128/AAC.01644-18
  21. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538-3545. https://doi.org/10.1128/AAC.00325-11
  22. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273-1280. https://doi.org/10.1128/AAC.05760-11
  23. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxoneresistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67(8):1858-1860. https://doi.org/10.1093/jac/dks162PMID:22566592
  24. Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850-1851. https://doi.org/10.1056/NEJMc1408109
  25. Deguchi T, Yasuda M, Hatazaki K, et al. New Clinical Strain of Neisseria gonorrhoeae with Decreased Susceptibility to Ceftriaxone, Japan. Emerg Infect Dis. 2016;22(1):142-144.  https://doi.org/10.3201/eid2201.150868
  26. Gianecini R, Oviedo C, Stafforini G, Galarza P. Neisseria gonorrhoeae Resistant to Ceftriaxone and Cefixime, Argentina. Emerg Infect Dis. 2016;22(6): 1139-1141. https://doi.org/10.3201/eid2206.152091
  27. Nakayama S, Shimuta K, Furubayashi K, Kawahata T, Unemo M, Ohnishi M. New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan. Antimicrob Agents Chemother. 2016;60(7):4339-4341. https://doi.org/10.1128/AAC.00504-16
  28. Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(2):381-383.  https://doi.org/10.3201/eid2402.171756
  29. Terkelsen D, Tolstrup J, Johnsen CH, et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Euro Surveill. 2017;22(42):1273. https://doi.org/10.2807/1560-7917.ES.2017.22.42.17-00659
  30. Lahra MM, Martin I, Demczuk W, et al. Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain. Emerg Infect Dis. 2018;24(4):735-743.  https://doi.org/10.3201/eid2404.171873
  31. Abrams AJ, Kirkcaldy RD, Pettus K, Fox JL, Kubin G, Trees DL. A Case of Decreased Susceptibility to Ceftriaxone in Neisseria gonorrhoeae in the Absence of a Mosaic Penicillin-Binding Protein 2 (penA) Allele. Sex Transm Dis. 2017;44(8):492-494.  https://doi.org/10.1097/OLQ.0000000000000645
  32. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20(1):S47-65.  https://doi.org/10.1093/clinids/20.Supplement_1.S47
  33. Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. Methods Mol Biol. 2019; 1997:37-58.  https://doi.org/10.1007/978-1-4939-9496-0_3
  34. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:19833.
  35. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59:1083-1091. https://doi.org/10.1093/cid/ciu521
  36. Ross JDC, Brittain C, Cole M, et al. G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet. 2019;393:2511-2520. https://doi.org/10.1016/S0140-6736(18)32817-4
  37. Unemo M, Jensen JS. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017;14: 139-152. 
  38. Unemo M, Lahra MM, Cole M, et al. World health organization global gonococcal antimicrobial surveillance program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health. 2019;16:412-425. 
  39. Bodoev IN, Il’ina EN. Molecular mechanisms of drug resistance formation in Neisseria gonorrhoeae: history and a look into the future. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2015;3:22-27. (In Russ.).
  40. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains including those with high-level antimicrobial resistance: potential treatment op. Antimicrob. Agents Chemother. 2012;56:2739-2742.
  41. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents. 2001;18:29-35. 
  42. Mitjà O, Suñer C, Giacani L, Vall-Mayans M, Tiplica GS, Ross JDC, Bradshaw CS. Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis. Lancet Reg Health Eur. 2023 Oct 26;34:100737. https://doi.org/10.1016/j.lanepe.2023.100737
  43. Taylor SN, Morris DH, Avery AK. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, doseranging, single-oral dose evaluation. Clin Infect Dis. 2018;67:504-512. 
  44. Bradford PA, Miller AA, O‘Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis. 2020;6:1332-1345.
  45. Jacobsson S, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections. Front Pharmacol. 2022; 13:1035841. https://doi.org/10.3389/fphar.2022.1035841
  46. European Centre for Disease Prevention and Contro (ECDC). Facts about chlamydia. Accessed Fev 17, 2025. https://www.ecdc.europa.eu/en/chlamydia/facts
  47. White JA, Dukers-Muijrers NHTM, Hoebe CJPA, Kenyon CR, Ross JDC, Unemo M. 2025 European guideline on the management of Chlamydia trachomatis infections. International Journal of STD & AIDS. 2025;0(0):1-16.  https://doi.org/10.1177/09564624251323678
  48. Klinicheskie rekomendatsii. Khlamidiinaya infektsiya. God utverzhdeniya: 2024. Accessed Fev 17, 2025. (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/194_2
  49. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59:193-205.  https://doi.org/10.1093/cid/ciu220
  50. Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. Cochrane Database Syst Rev. 2019;1:CD010871. https://doi.org/10.1002/14651858.CD010871.pub2
  51. Dukers-Muijrers NHTM, Wolffs PFG, De Vries H, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal Chlamydia trachomatis infections in women: a multicentre observational study (FemCure). Clin Infect Dis. 2019;69:1946-1954. https://doi.org/10.1093/cid/ciz050
  52. Dombrowski JC, Wierzbicki MR, Newman LM, et al. Doxycycline versus azithromycin for the treatment of rectal chlamydia in men who have sex with men: a randomized controlled trial. Clin Infect Dis. 2021;ciab153. https://doi.org/10.1093/cid/ciab153
  53. Dukers-Muijrers NH, Schachter J, van Liere GA, Wolffs PF, Hoebe CJ. What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC Infect Dis. 2015;15:533.  https://doi.org/10.1186/s12879-015-1280-6
  54. Rank RG, Yeruva L. An alternative scenario to explain rectal positivity in Chlamydia-infected individuals. Clin Infect Dis. 2015;60:1585-1586. https://doi.org/10.1093/cid/civ079
  55. Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. Clin Infect Dis. 2012;55:82-88. PMID:22431798/ https://doi.org/10.1093/cid/cis291
  56. Ejdel’shtejn IA, Ejdel’shtejn MV, Shipicyna EV, Husnutdinova TA, Savicheva AM, Kozlov RS. Assessment of the prevalence of «classical» mechanisms of resistance to fluoroquinolones in Chlamydia trachomatis associated with mutations in topoisomerase genes. Klin mikrobiol antimikrob himioter. 2014;6(4):287-293. (In Russ.).
  57. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis. 2005;191(6):917-923. 
  58. Satoshi Takahashi, Ryoichi Hamasuna, Mitsuru Yasuda, et al. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan. J Infect Chemother. 2016 Sep;22(9):581-586.  https://doi.org/10.1016/j.jiac.2016.06.010
  59. Berger-Bächi B. Expression of resistance to methicillin. Trends Microbiol. 1994;2(10):389-393. 
  60. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181(4):1421-1427.
  61. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother. 2003;47(2):636-642. 
  62. Shipitsyna EV, Savicheva AM. Antibiotic resistance of Chlamydia trachomatis. Zhurnal akusherstva i zhenskikh boleznei. 2002;51(4):77-83. (In Russ.).
  63. Benamri I, Azzouzi M, Sanak K, Moussa A, Radouani F. An overview of genes and mutations associated with Chlamydiae species” resistance to antibiotics. Ann Clin Microbiol Antimicrob. 2021;20(1):59. 
  64. Fabian Yuh Shiong Kong, Jane Simone Hocking. Treatment challenges for urogenital and anorectal Chlamydia trachomatis BMC Infectious Diseases. 2015;15:293.  https://doi.org/10.1186/s12879-015-1030-9
  65. Khosropour CM, Manhart LE, Colombara DV, et al. Sub-optimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect. 2014;90(1):3-7. 
  66. Barry PM, Kent CK, Philip SS, Klausner JD. Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol. 2010;115(4): 753-759. 
  67. Manavi K. A review on infection with Chlamydia trachomatis. Best Pract Res Cl Ob. 2006;20(6):941-951. 
  68. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health. 2011;8(1):69-73. 
  69. Caldwell HD, Wood H, Crane D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest. 2003;111(11):1757-1769.
  70. Fehlner-Gardiner C, Roshick C, Carlson JH, et al. Molecular basis defining human chlamydia trachomatis tissue tropism: A possible role for tryptophan synthase. J Biol Chem. 2002;277(30):26893-26903.
  71. Kintner J, Lajoie D, Hall J, Whittimore J, Schoborg RV. Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations. Front Cell Infect Microbiol. 2014;4:44. 
  72. Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun. 2004;72(4):1843-1855.
  73. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201(2):S88-95. 
  74. Vodstrcil LA, McIver R, Huston WM, Tabrizi SN, Timms P, Hocking JS. The epidemiology of organism load in genital Chlamydia trachomatis infection — a systematic review. J Infect Dis. 2015;211(10):1628-1645.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.